Skip to main content
Menu
US

AlphaLISA SureFire Ultra Human Total EGFR L858R Detection Kit, 500 Assay Points

The AlphaLISA™ SureFire® Ultra™ Human Total EGF Receptor L858R assay is a sandwich immunoassay for quantitative detection of total EGF Receptor L858R in cellular lysates using Alpha Technology.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Feature Specification
Application Cell Signaling
Sample Volume 10 µL

The AlphaLISA™ SureFire® Ultra™ Human Total EGF Receptor L858R assay is a sandwich immunoassay for quantitative detection of total EGF Receptor L858R in cellular lysates using Alpha Technology.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Product Variants
Unit Size: 500 Assay Points
Part #:
ALSU-TEGFR-B500
List Price
USD 2,346.00
Unit Size: 10,000 Assay Points
Part #:
ALSU-TEGFR-B10K
List Price
USD 14,270.00
Unit Size: 50,000 Assay Points
Part #:
ALSU-TEGFR-B50K
List Price
USD 46,060.00
Unit Size: 100 Assay Points
Part #:
ALSU-TEGFR-B-HV
List Price
USD 694.44

Overview

Epidermal growth factor receptor (EGFR, EGF Receptor, Erb-1, or HER1) is a transmembrane protein and receptor for members of the epidermal growth factor (EGF) family. Binding of EGFR ligands drives receptor homodimerization or hetero-dimerization, leading to the activation of the EGFR tyrosine kinase domain and specific tyrosine residues. The signals transmitted from the EGF receptor to the nucleus lead to the regulation of various biological functions, such as cell proliferation, differentiation, survival, adhesion, migration, and angiogenesis. Mutations in EGFR, including mutation L858R in exon 21, result in EGFR overexpression and are associated with cancer.

The AlphaLISA SureFire Human Total EGF Receptor L858R Detection Kit is a sandwich immunoassay for the quantitative detection of total EGF Receptor L858R in cellular lysates, using Alpha Technology.

Formats
  • The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
  • The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
  • The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
  • The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.
AlphaLISA SureFire Ultra kits are compatible with
  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies
Alpha SureFire kits can be used for
  • Cellular kinase assays
  • Receptor activation studies
  • Screening

Specifications

Application
Cell Signaling
Automation Compatible
Yes
Brand
AlphaLISA SureFire Ultra
Detection Modality
Alpha
Lysis Buffer Compatibility
Lysis Buffer
Molecular Modification
Total
Product Group
Kit
Sample Volume
10 µL
Shipping Conditions
Shipped in Blue Ice
Target
EGF Receptor
Target Class
Phosphoproteins
Target Species
Human
Technology
Alpha
Therapeutic Area
Immuno-oncology
Oncology
Unit Size
500 Assay Points

Video gallery

Resources

Are you looking for resources, click on the resource type to explore further.

1-2 of 2 Resources
Application Note Icon
Application Note
Characterizing Chemokine Receptor Inhibitors with AlphaLISA SureFire Ultra

Therapeutic antibodies directed to cell surface receptors are increasingly being developed as treatments for a variety of diseases...

Application Note Icon
Application Note
Characterizing chemokine receptor inhibitors with AlphaLISA SureFire Ultra, Alpha SureFire Ultra Multiplex and LANCE Ultra cAMP assays

The measurement of protein phosphorylation is a useful tool for measuring the modulation of receptor activation by both antibodies...

Scroll Icon